Open Access

High ERCC1 expression is associated with platinum‑resistance, but not survival in patients with epithelial ovarian cancer

  • Authors:
    • Pei Du
    • Yifeng Wang
    • Liquan Chen
    • Yaping Gan
    • Qinian Wu
  • View Affiliations

  • Published online on: June 15, 2016     https://doi.org/10.3892/ol.2016.4732
  • Pages: 857-862
  • Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the association between excision repair cross-complementation group 1 (ERCC1) expression and clinical resistance to platinum‑based chemotherapy or clinical characteristics, including survival time, in patients with epithelial ovarian cancer (EOC). ERCC1 expression was determined by immunohistochemical staining in 92 tumor specimens from patients with EOC. The effect of ERCC1 expression on progression‑free survival time (PFS) or overall survival time (OS), and its association with clinical resistance to platinum‑based chemotherapy was investigated by Kaplan‑Meier survival analysis, Cox regression analysis and the χ2 test. Of 92 patients with EOC, 89.13% (82/92) had ERCC1‑positive tumors. The positive rate was significantly higher in platinum‑resistant patients compared with those who were platinum‑responding (P<0.05). The PFS and median OS were 12 and 30 months, respectively, in ERCC1 high expression patients, and 17 and 39 months, respectively, in ERCC1 low expression patients. However, there was no statistically significant difference in PFS (P=0.099) or OS (P=0.103) between the high and low expression groups. Furthermore, it was identified that ERCC1 was not an independent factor affecting the prognosis of patients with EOC based on Cox proportional hazards regression analysis. These results demonstrate that high ERCC1 expression is associated with resistance to platinum‑based chemotherapy, but not with survival time, and ERCC1 protein expression is not an independent factor or the only factor affecting the prognosis of patients with EOC.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Du P, Wang Y, Chen L, Gan Y and Wu Q: High ERCC1 expression is associated with platinum‑resistance, but not survival in patients with epithelial ovarian cancer. Oncol Lett 12: 857-862, 2016
APA
Du, P., Wang, Y., Chen, L., Gan, Y., & Wu, Q. (2016). High ERCC1 expression is associated with platinum‑resistance, but not survival in patients with epithelial ovarian cancer. Oncology Letters, 12, 857-862. https://doi.org/10.3892/ol.2016.4732
MLA
Du, P., Wang, Y., Chen, L., Gan, Y., Wu, Q."High ERCC1 expression is associated with platinum‑resistance, but not survival in patients with epithelial ovarian cancer". Oncology Letters 12.2 (2016): 857-862.
Chicago
Du, P., Wang, Y., Chen, L., Gan, Y., Wu, Q."High ERCC1 expression is associated with platinum‑resistance, but not survival in patients with epithelial ovarian cancer". Oncology Letters 12, no. 2 (2016): 857-862. https://doi.org/10.3892/ol.2016.4732